#	Pagina
attuale pagina	/open-h2020/projects/218274/index.html
-1	/open-h2020/projects/220138/index.html
-2	/open-h2020/projects/217921/index.html
-3	/open-h2020/projects/210078/index.html
-4	/open-h2020/projects/216334/index.html
-5	/open-h2020/projects/224942/index.html
-6	/open-h2020/projects/199568/index.html
-7	/open-h2020/projects/224251/index.html
-8	/open-h2020/projects/220607/index.html
-9	/open-h2020/projects/224053/index.html
-10	/open-h2020/projects/211060/index.html

Opendata, web and dolomites

CytoPro SIGNED

A breakthrough cancer diagnostic instrument to save 3000 years of human lives annually and up

Total Cost €

EC-Contrib. €

Partnership

Views

CytoPro project word cloud

Explore the words cloud of the CytoPro project. It provides you a very rough idea of what is the project "CytoPro" about.

colorectal benefit expensive isolate 13m rapid monitor record genetic commercialising survival successfully oncologists trade date device biopsies treatments ing generate people effectiveness time cytopro mcrc 20 41m fighting approved revenue proven detect ctc 15 track clinical 2026 invasive rates business half diagnostic ct11 billion bloodstream introduction patient 2020 trials market refine profit tumours generation prepare lifetimes skills innovations circulating clinically blood select validate cancer society approximately save avoiding whilst team ctcs treatment 5bn optimise first enviable metastatic cells possesses tumour cytotrack successful tool right annual helps therapies mutations environment unnecessary ineffective medical assembled

Project "CytoPro" data sheet

The following table provides information about the project.

Coordinator	CYTOTRACK APS Organization address address: GAMMEL LUNDTOFTEVEJ 1D city: LYNGBY postcode: 2800 website: www.cytotrack.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Total cost	2˙445˙232 €
EC max contribution	1˙711˙662 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-11-01 to 2021-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CYTOTRACK APS CYTOTRACK APS Organization address address: GAMMEL LUNDTOFTEVEJ 1D city: LYNGBY postcode: 2800 website: www.cytotrack.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (LYNGBY)	coordinator	1˙692˙762.00
2	HVD BIOTECH VERTRIEBSGESELLSCHAFT MBH HVD BIOTECH VERTRIEBSGESELLSCHAFT MBH Organization address address: WURZBACHG 18 city: WIEN postcode: 1150 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	participant	18˙900.00

Map

Project objective

In Europe, approximately 1 in 2 people will get cancer in their lifetimes. State-of-the-art cancer treatments can be tailored to the genetic make-up of a patient’s tumour, making them highly effective at fighting cancer. However, these very expensive treatments, which cost the society €1.5bn each year, can become ineffective over time due to genetic mutations in the tumours. Currently, there is no diagnostic tool available to regularly monitor for such mutations.

CytoTrack has developed the CT11™, a unique blood test that helps oncologists to detect and monitor tumour mutations, enabling them to select the right treatment at the right time. The CT11™ can rapidly identify and isolate Circulating Tumour Cells (CTCs) in the bloodstream to provide up-to-date genetic information without invasive biopsies. Whilst our technology has been proven in the research environment, this CytoPro project will refine, demonstrate and clinically validate the CT11™ for use in metastatic Colorectal Cancer (mCRC) and prepare the device for clinical market introduction.

A successful project will make the CT11™ the first next-generation cancer blood test on the clinical market. It will allow oncologists to optimise therapies more quickly in response to tumour mutations, extending survival rates up to half a year, avoiding unnecessary side-effects and increasing cost effectiveness of the treatment by 10-20%, which could save €15,000 per treatment.

The market for CTC technology is expected to reach €7.8 billion by 2020 and, as the first clinically approved device of its type, we expect the CT11™ to generate rapid business growth for CytoTrack, resulting in an annual revenue of €41m and a profit of €13m by 2026.

The team assembled for CytoPro has an enviable track record in commercialising medical innovations and possesses all the skills and resources to successfully deliver the clinical trials and effectively exploit the results for the benefit of our business and for Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYTOPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYTOPRO" are provided by the European Opendata Portal: CORDIS opendata.